BASIC AND CLINICAL STUDIES ON BAY o 9867 (CIPROFLOXACIN) IN URINARY TRACT INFECTION
スポンサーリンク
概要
- 論文の詳細を見る
MICs of BAY o 9867 (Ciprofloxacin), Ofloxacin (OFLX) and Norfloxacin (NFLX) against 270 strains such as <I>S. epidermidis, S. faecalis, E. coli, K. pneumoniae, C. freundii, E. cloacae, P.mirabilis, P.vulgaris, S. marcescens</I> and <I>P.aeruginosa</I>were measured by agar dilution method. Each species consisted of 27 strains. Peak MICs of BAY o 9867 against these various species ranged from≤0.1 to 1.56 μg/ml and from 0.1 to 0.78 μg/ml with the inoculum size of 10<SUP>8</SUP>cells/ml and 10<SUP>6</SUP>cells/ml. BAY o 9867 seemed to have same or more than 2 fold stronger activity than OFLX and NFLX against all kinds of species tested.<BR>200mg of BAY o 9867 or NFLX was given orally to 7 male adult volunteers by cross-rver method. Serum peak level of BAY o 9867 reached 0.78 μg/ml after dosing and serum half life was proved 3.57 hours. Urinary recovery rate up to 12 hours was counted 43.0% and maximum urinary concentration rose to 294 μg/ml during first 2 hours. Both serum level and urinary recovery rate of this drug were higher than those of NFLX.<BR>Clinical efficacy and adverse effects were evaluated in 17 cases including 2 acute simple cystitis, 12 chronic complicated UTIs, 2 male genital infection and a cervicitis. According to the criterion of the second edition recommended by Japanese UTI committee, overall clinical efficacy of a case with acute simple cystitis showed moderate. Of 5 cases with chronic complicated UTIs showed excellent in 2 cases and moderate in a case. A case with gonorrheal urethritis and a case with chronic prostatitis were proved to be excellent and fair respectively by Dr's evaluation. No adverse effect and no abnormal clinical laboratory test were observed after giving this drug.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.